Most of the evidence on this site is preclinical, and the standing complaint about TUDCA is that almost nobody has run a proper human trial. Parenteral nutrition-associated cholestasis is the exception, and it is worth a page for exactly that reason: TUDCA was tested here, in neonates, in a randomised comparison, and it did not work.
That is an unusual thing to find in supplement territory, and it is more informative than another mouse study. This page covers what the trial did, why it probably failed, and what the result does and does not imply for the other cholestatic conditions where TUDCA has a better record, including the head-to-head comparison against ursodeoxycholic acid in drug-induced liver injury. It is hospital medicine throughout, not a supplement decision.
Key Takeaways
- In a 2002 study, 22 infants on total parenteral nutrition received enteral TUDCA at 30 mg/kg/day and were compared with 30 untreated or placebo controls[1].
- There was no difference in peak conjugated bilirubin, ALT, alkaline phosphatase or bile acids between treated and control infants, and none after stratifying by birth weight above and below 1500 g[1].
- Conjugated bilirubin was similar between groups after 14, 40, 60, 70 and 120 days of parenteral nutrition. The authors concluded TUDCA appears ineffective for preventing or treating this condition[1].
- The authors named a likely reason: erratic biliary enrichment and a prolonged inability to start treatment may compromise enterally administered TUDCA in these infants[1].
- The parent compound has not fared much better in prevention. A 2024 systematic review and meta-analysis found UDCA prophylaxis did not reduce cholestasis, mortality, sepsis or necrotising enterocolitis, with low to very low certainty evidence[2].
- TUDCA does work in another cholestatic setting. In a 199-patient randomised double-blind trial in primary biliary cholangitis, it matched UDCA on the primary endpoint[3].
What the Condition Is
Parenteral nutrition keeps people alive who cannot absorb food through the gut. In infants especially, prolonged use is complicated by cholestatic liver disease. A review of the field describes damage that is often mild and resolves when parenteral nutrition is stopped, but which in some cases, particularly in neonates and infants, progresses to cirrhotic change[4]. The clinical problem is what to do when parenteral nutrition cannot be stopped.
Bile acids are an obvious candidate because the disorder is a bile flow problem, and choleretic activity is one of the better-documented things TUDCA does. The same review notes that UDCA has been proposed in these patients but that its efficacy needs to be better established, and that lipid emulsions high in long-chain omega-3 fatty acids appear effective at improving biliary flow[4].
The Trial
The design was straightforward. Infants were enrolled after surgery, while serum direct bilirubin was still below 2 mg/dL, so treatment started before the liver injury appeared. Dosing ahead of the insult is a recurring design choice in this literature: every relevant study in the pancreatitis work made the same choice. Twenty-two received TUDCA enterally at 30 mg/kg/day. A concurrent untreated or placebo group of 30 served as comparison. Blood chemistry including ALT, alkaline phosphatase, conjugated bilirubin and bile acids was drawn weekly[1].
Nothing separated the groups. There was no difference in peak conjugated bilirubin, ALT, alkaline phosphatase or bile acid levels. Stratifying by birth weight above and below 1500 g did not reveal a subgroup that responded. Conjugated bilirubin tracked together at 14, 40, 60, 70 and 120 days of parenteral nutrition. The conclusion was that TUDCA appears ineffective in preventing the development or treating this form of cholestasis[1].
A negative trial with 22 treated infants is not proof of absence, and it is worth saying so. But this was a prospective comparison with a concurrent control group and a prespecified biochemical endpoint, and it started treatment early rather than as rescue. That is a fair test, and it failed.
Why It Probably Failed, Which Is the Interesting Part
The authors offered their own explanation: erratic biliary enrichment, and a prolonged inability to initiate treatment, may compromise the utility of enterically administered TUDCA in infants on parenteral nutrition[1]. Both halves of that sentence are mechanical rather than pharmacological.
An orally or enterally delivered bile acid has to be absorbed from the intestine to reach the liver and enter the bile. In a human absorption study, eight patients with complete extrahepatic biliary obstruction and biliary drainage received 1000 mg of TUDCA and 750 mg of UDCA in random order. About 64.6 percent of the TUDCA and 55.1 percent of the UDCA was absorbed, a difference that was not statistically significant, and biliary content of UDCA rose to a little over half of total bile acids either way[5]. Absorption of that kind depends on a functioning gut. An infant sick enough to need long-term parenteral nutrition is, by definition, an infant whose gut is not working normally, which is the absorption question in its most extreme form.
That reading is supported by an incidental finding from a small retrospective series of six preterm infants treated with UDCA: consistent improvement across all infants was noted only after 10 days of full enteral nutrition[6]. The bile acid looked like it was working once the gut was working.
How the Parent Compound Has Done
UDCA is the more commonly used drug here, and the prevention evidence is weak. A 2024 systematic review and meta-analysis found five eligible studies, three randomised and two not. The randomised evidence showed UDCA prophylaxis did not reduce cholestasis, mortality, sepsis or necrotising enterocolitis. It did reduce feed intolerance, peak conjugated bilirubin by 0.13 mg/dL and time to full enteral feeds by 2.7 days. The non-randomised data showed no benefit on any outcome, and the authors rated certainty low to very low and declined to draw definitive conclusions[2].
Treatment, as opposed to prevention, looks better. A large review of UDCA in children with cholestasis of any cause pooled 32 randomised trials and 2153 patients, reporting improvement in symptoms and in liver biochemistry, with gastrointestinal adverse reactions in about 10.6 percent and no significant difference in adverse events against placebo[7]. A retrospective cohort found that combining UDCA with a lipid emulsion low in phytosterols significantly shortened the duration of cholestasis[8], which fits the review conclusion that the emulsion may matter more than the bile acid[4].
What This Does Not Mean
A negative result in one condition is not a verdict on a compound. In primary biliary cholangitis, 199 patients were randomised to 250 mg of TUDCA or 250 mg of UDCA three times daily for 24 weeks. At week 24, 75.97 percent of the TUDCA group and 80.88 percent of the UDCA group achieved the primary endpoint of an alkaline phosphatase reduction greater than 25 percent, a difference that was not significant, and both drugs were well tolerated[3]. A smaller randomised trial in liver cirrhosis at 750 mg/day for six months reported reductions in ALT, AST and ALP in the TUDCA arm[9].
So the compound is capable of acting in cholestatic liver disease in adults who absorb it. The PBC trial page covers that evidence in detail. What the parenteral nutrition result adds is a specific and transferable lesson: a bile acid that has to be absorbed will underperform in exactly the patients whose absorption is compromised.
Frequently Asked Questions
Does TUDCA prevent parenteral nutrition-associated cholestasis?
No, on the available evidence. Twenty-two infants given 30 mg/kg/day enterally showed no difference from 30 controls in peak conjugated bilirubin, ALT, alkaline phosphatase or bile acids, and the authors concluded it appears ineffective[1].
Why did it work in primary biliary cholangitis but not here?
The most likely reason is delivery rather than biology. The trial authors pointed to erratic biliary enrichment and delayed treatment initiation[1], and enteral absorption of a bile acid depends on a functioning gut[5]. Adults with primary biliary cholangitis absorb their dose normally, and there TUDCA matched UDCA[3].
Is UDCA better for this condition?
For prevention, the randomised evidence says no clear benefit on cholestasis, mortality or sepsis, at low to very low certainty[2]. For treating established cholestasis in children it performs better across a much larger pooled dataset[7], and combining it with a low-phytosterol lipid emulsion shortened cholestasis duration in one retrospective series[8].
Does this negative result matter for healthy adults taking TUDCA?
Only as a reminder that absorption is the rate-limiting step. The finding is specific to critically ill neonates who are not being fed enterally. It says nothing about whether TUDCA helps an adult with a normal gut, and it is not a safety signal.
References
- Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr (2002).
- Ursodeoxycholic acid for preventing parenteral nutrition-associated cholestasis in neonates: A systematic review and meta-analysis. Fundam Clin Pharmacol (2024).
- A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore) (2016).
- Pediatric parenteral nutrition-associated liver disease and cholestasis: Novel advances in pathomechanisms-based prevention and treatment. Dig Liver Dis (2016).
- Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate. Eur J Clin Invest (2002).
- Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. J Pediatr Endocrinol Metab (1999).
- Efficacy and safety of ursodeoxycholic acid in children with cholestasis: A systematic review and meta-analysis. PLoS One (2023).
- Ursodeoxycholic Acid and SMOFlipid for Treating Parenteral Nutrition Associated Cholestasis in Infants. Cureus (2022).
- Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci (2013).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
